In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants.
about
Evolution of phage with chemically ambiguous proteomesEmergence of primary NNRTI resistance mutations without antiretroviral selective pressure in a HAART-treated childIdentification of drug resistant mutations in HIV-1 CRF07_BC variants selected by nevirapine in vitroComparison of laboratory methods for analysis of non-nucleoside reverse transcriptase inhibitor resistance in Ugandan infantsDivergent evolution in reverse transcriptase (RT) of HIV-1 group O and M lineages: impact on structure, fitness, and sensitivity to nonnucleoside RT inhibitors.HIV-1 diversity after a class switch failure.Commentary on the role of treatment-related HIV compensatory mutations on increasing virulence: new discoveries twenty years since the clinical testing of protease inhibitors to block HIV-1 replication.Select resistance-associated mutations in blood are associated with lower CSF viral loads and better neuropsychological performance.Adherence-resistance relationships to combination HIV antiretroviral therapy.Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.HIV Genetic Diversity and Drug Resistance.Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period.Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy.Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispeciesHIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure.Viremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern IndiaClinical significance of human immunodeficiency virus type 1 replication fitness.Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations.The contribution of HIV fitness to the evolution pattern of reverse transcriptase inhibitor resistance.Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs.Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants.In vitro selection of HIV-1 CRF08_BC variants resistant to reverse transcriptase inhibitors.Recombination in feline lentiviral genomes during experimental cross-species infection.Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study.
P2860
Q24804563-3437A3F7-2548-4EA7-A25C-545DB0E6C705Q28474989-2B48B748-0344-460E-981C-DA3A179AE516Q28483726-E3A1194B-A03C-4A9D-B9F1-7A5882A4A8F6Q33561750-6B1B6422-12CC-4A10-B66F-AD6C09B96B72Q34120878-E4A3470D-EB74-4BB2-9818-309848295686Q34399268-E00F9C7C-34F5-4062-BC9B-E6C964A84A45Q34432377-8BEE24C5-C847-41BE-9205-3780BA42CD10Q34615228-0AC1C9EC-874D-48CC-9B39-372CFACF7522Q34634212-CFD2FD95-7B36-4693-915F-BA5897E4AF58Q34737547-B2E686DE-198E-41D0-9F6F-C885AF7399D8Q35260590-357A80F9-3358-47A9-8094-3CEAC9E6F077Q35827900-A750E335-6567-4D02-84D3-1420E12EC8B7Q35842525-E808E8BE-B426-46E2-A21F-6B31E18A81BBQ35947480-1B2DACD0-8DBC-4523-9E17-DE8B97B82B00Q36559608-D9D5D5B0-F7D9-4C02-8D54-A2F9136E3173Q36607276-2E314A0A-894A-46AB-930E-34BCCEF52C9DQ36607906-17A73929-6909-4F4D-B9E9-C9B299F39BD7Q36969857-EAAF3573-94C5-4C27-A074-9CCEC2B4CE07Q37859395-B39C2573-AA54-48A6-B0D5-7167DEF67ED0Q40315440-5C2D603D-0DFB-4834-8D36-7A549DA0820CQ40410591-7478FAFF-EC1D-4938-9748-BDD5573D0F75Q40674710-C6E89F1F-F2DB-4BE4-BB4A-887001923C30Q41720036-1977F9E4-B250-4601-BB1D-B13B253AED93Q41877700-1A79F68D-1423-47B8-ABDE-3C22EA233B71Q45060352-54787A29-7F84-42C9-B5C4-24C62118286F
P2860
In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
In vitro analysis of human imm ...... ination of resistant variants.
@en
In vitro analysis of human imm ...... ination of resistant variants.
@nl
type
label
In vitro analysis of human imm ...... ination of resistant variants.
@en
In vitro analysis of human imm ...... ination of resistant variants.
@nl
prefLabel
In vitro analysis of human imm ...... ination of resistant variants.
@en
In vitro analysis of human imm ...... ination of resistant variants.
@nl
P2093
P1476
In vitro analysis of human imm ...... ination of resistant variants.
@en
P2093
Cecilio López-Galíndez
Concepción Casado
Eloísa Yuste
Isabel Olivares
Maria Dolores Iglesias-Ussel
P304
P356
10.1099/0022-1317-83-1-93
P407
P577
2002-01-01T00:00:00Z